|
For decades, scientists warned of the potential for a global coronavirus outbreak. But when SARS-CoV-2 emerged, no therapeutics, drugs, or vaccines were readily available. The Rapidly Emerging Antiviral Drug Development Initiative (READDI) — founded by researchers at UNC and the Structural Genomics Consortium — is not only finding solutions to the COVID-19 pandemic, but also drugs and therapeutics for future viral outbreaks.
Watch the full video here. John Bamforth oversees the Rapidly Emerging Antiviral Drug Discovery Initiative, a non-profit drug research and development organization that is part of the Eshelman Institute for Innovation.
The mission: to find treatments for COVID-19 and to anticipate what treatments may be needed in future pandemics. Tech Transfer Central's University-Industry Engagement Advisor highlights READDI's strategic approach to planning for future pandemics.
John Bamforth, director, Eshelman Institute for Innovation, University of North Carolina, Chapel Hill, discusses with University/Industry Demonstration Partnership (UIDP) what it takes to bring together the world's top pharmaceutical researchers and industry leaders to ensure we're ready for future pandemics.
North Carolina Policy Collaboratory distributes $29 million for COVID-19 research
The Collaboratory funded 85 projects across 14 UNC System schools, including $1 million allocated to each of the six Historically Minority-Serving Institutions. |
READDI is led by The University of North Carolina at Chapel Hill.
|
